Open-Label, Safety Study of Lofexidine
Public ClinicalTrials.gov record NCT02363998. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-Label, Safety Study of Lofexidine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.
Study identification
- NCT ID
- NCT02363998
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 286 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2015 (Actual)
- Primary completion
- Sep 2015 (Actual)
- Completion
- Oct 2015 (Actual)
- Last update posted
- Mar 22, 2022
2015
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72211 | — |
| Not listed | Springdale | Arkansas | 72764 | — |
| Not listed | San Diego | California | 92103 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Hollywood | Florida | 33021 | — |
| Not listed | Orlando | Florida | 32801 | — |
| Not listed | Atlanta | Georgia | 30331 | — |
| Not listed | Winfield | Illinois | 60190 | — |
| Not listed | Lake Charles | Louisiana | 70629 | — |
| Not listed | Rockville | Maryland | 20853 | — |
| Not listed | Flowood | Mississippi | 39232 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | New York | New York | 10019 | — |
| Not listed | Dayton | Ohio | 45417 | — |
| Not listed | Portland | Oregon | 97214 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213 | — |
| Not listed | North Charleston | South Carolina | 29405 | — |
| Not listed | Orem | Utah | 84058 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02363998, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02363998 live on ClinicalTrials.gov.